Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots Analysis
Growing at an annualized rate of over 16.5%, the cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030, claims Roots Analysis
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies.


Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition),2019 - 2030” reportto its list of offerings.


Owing to variousreasons, the demand for cell therapies is anticipated to increase over the comingyears. Therefore, both therapy developers and contract service providers mayneed to strengthen their capabilities and expand available capacity. In thiscontext, automation is expected to be a key enabler within the cell therapymanufacturing and contract services industry.


To order this 550+ page report, which features160+ figures and 250+ tables, please visit this link



Key Market Insights


More than 160 organizationsclaim to be engaged in cell therapy manufacturing

The market landscapeis dominated by industry players, representing more than 60% of the totalnumber of stakeholders. Amongst these, over 55 are large or mid-sized firms (havingmore than 50 employees).


100+ players focused on T-cell and stem cell therapies

Most of these playersare focused on manufacturing T-cell therapies, including CART, TCR or TILs. Itis worth highlighting that more than 35 organizations claim to have necessary capabilitiesfor the manufacturing of both types of therapies.


Presently, 70+ companies have commercial scale capacity

As majority of the celltherapy products are in clinical trials, the demand is high at this scale. However,it is worth noting that several players (~50%) have already developedcommercial scale capacity for cell therapies.


Europe is currently considered a current hub for celltherapy production

More than 220manufacturing facilities have been established by various players, worldwide; ofthese, 35% are in Europe, followed by those based in North America. Otheremerging regions include Australia, China, Japan, Singapore, South Korea andIsrael.


50+ facility expansions reported between 2015-2019

More than 85% of theexpansions are related to setting up of new facilities across differentregions. Maximum expansion activity was observed in the US and in certaincountries within the Asia Pacific regions.

20+ companies offer automatedsolutions to cell therapy developers

Players that claim tooffer consultancy services related to automation include (in alphabeticalorder) Berkeley Lights, Cesca Therapeutics, Ferrologix, FluDesign Sonics,GE Healthcare and Terumo BCT. Further, we identified players, namely (inalphabetical order) Fraunhofer Institute for Manufacturing Engineering andAutomation IPA, Invetech, KMC Systems, Mayo Clinic Center for RegenerativeMedicine and RoosterBio, that offer consultancy solutions related toautomation.


Partnership activityhas grown at an annualized rate of 16%, between 2014 and 2018

More than 200agreements have been inked in the last 5 years; majority of these were focused onthe supply of cell-based therapy products for clinical trials. Other popular typesof collaboration models include manufacturing process development agreements (16%),services agreements (12%) and acquisitions (10%).


By 2030, developedgeographies will capture over 60% of the market share

Asia Pacific isanticipated to capture the major share (~36%) of the market by 2030. It is alsoimportant to highlight that financial resources, technical expertise and establishedinfrastructure is likely to drive cell therapy manufacturing market in Europe,which is estimated to grow at a CAGR of ~26%.


To request a samplecopy / brochure of this report, please visit this link       


KeyQuestions Answered

§ What is the global demand for cell-based therapies?

§ Who are the key manufacturers (industry / non-industry) ofcell-based therapies, across the world?

§ What are the major recent developments (such aspartnerships and expansions) in this industry?

§ What kind of partnership models are commonly adopted bystakeholders in this domain?

§ What is the current, installed contract manufacturingcapacity for cell therapies?

§ What are the key factors influencing the make(manufacture in-house) versus buy (outsource) decision related to celltherapies?

§ What are the key parameters governing the cost of celltherapy manufacturing?

§ What are important technology platforms (available / underdevelopment) for cell therapy development and manufacturing?

§  Whatare the key drivers and growth constraints in cell therapy manufacturing market?

§ How is the current and future market opportunity likely tobe distributed across key market segments?


The USD 11 billion (by 2030) financial opportunitywithin the cell therapy manufacturing market has been analyzed across thefollowing segments:

§  Typeof therapy

§  T-celltherapies (CAR-T therapies, TCR therapies, TIL therapies)

§  Dendriticcell therapies

§  Tumorcell therapies

§  NKcell therapies

§  Stemcell therapies


§ Source of cells

§ Autologous

§ Allogeneic


§  Scaleof operation

§ Clinical

§ Commercial


§  Purposeof manufacturing

§ Contract manufacturing

§ In-house manufacturing


§  Keygeographical regions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the world


The report featuresinputs from eminent industry stakeholders, according to whom the manufacturingof cell therapies is largely being outsourced due to exorbitant costsassociated with the setting-up of in-house expertise. The report includesdetailed transcripts of discussions held with the following experts:

§ Victor Lietao Li (Co-Founder and Chief Executive Officer,Lion TCR)

§ Tim Oldham (Chief Executive Officer, Cell Therapies)

§ Gerard MJ Bos (Chief Executive Officer, CiMaas)

§ Wei (William) Cao (Chief Executive Officer, GracellBiotechnologies)

§ Troels Jordansen (Chief Executive Officer, GlycostemTherapeutics)

§ Arik Hasson (Executive VP Research and Development, Kadimastem)

§ Gilles Devillers (General Manager, Bio Elpida)

§ Arnaud Deladeriere (Manager, Business Development &Operations-cGMP Manufacturing Unit, Center of Excellence for Cellular Therapy /C3i)

§ Brian Dattilo (Manager of Business Development, WaismanBiomanufacturing)

§ Fiona Bellot (Business Development Manager, RoslinCT)

§ Mathilde Girard (Department Leader, Cell Therapy Innovationand Development, YposKesi)

§ David Mckenna (Professor and American Red Cross Chair inTransfusion Medicine, University of Minnesota)


The research coversprofiles of key players (industry and non-industry) that offer manufacturingservices for cell-based therapies, featuring a company overview, information onmanufacturing facilities, and recent collaborations.

§ BioNTech Innovative Manufacturing Services

§ Cell Therapies

§ Cell and Gene Therapy Catapult

§ Center for Cell and Gene Therapy, Baylor College ofMedicine

§ Centre for Cell Manufacturing Ireland, National Universityof Ireland

§ Clinical Cell and Vaccine Production Facility, Universityof Pennsylvania

§ Cognate BioServices


§ Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital

§ Hitachi Chemical

§ KBI Biopharma

§ Laboratory for Cell and Gene Medicine, Stanford University

§ Lonza

§ MaSTherCell


§ Molecular and Cellular Therapeutics, University ofMinnesota

§ Newcastle Cellular Therapies Facility, Newcastle University

§ Nikon CeLL innovation

§ Rayne Cell Therapy Suite, King’s College London

§ Roslin Cell Therapies

§ Scottish National Blood Transfusion Services CellularTherapy Facility, Scottish Centre for Regenerative Medicine

§ Sydney Cell and Gene Therapy

§ WuXi Advanced Therapies


For additionaldetails, please visit


You may also beinterested in the following titles:

1.    Cell and AdvancedTherapies Supply Chain Management Market, 2019-2030

2.    RNAi TherapeuticsMarket (2nd Edition), 2019 – 2030

3.    Gene Therapy Market(3rd Edition), 2019 – 2030

4.    Stem Cell TherapyContract Manufacturing Market, 2019-2030



Gaurav Chaudhary

+1 (415) 800 3415